Drug Profile


Alternative Names: LY 213829

Latest Information Update: 06 Jul 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer Shire Pharmaceuticals Group
  • Class Anti-inflammatories; Irritable bowel syndrome therapies; Phenols; Thiazolidines
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Crohn's disease; Irritable bowel syndrome; Ulcerative colitis

Most Recent Events

  • 06 Jul 2000 Discontinued-II for Irritable bowel syndrome in USA (Rectal)
  • 21 Jun 2000 Tazofelone is available for licensing (http://www.shire.com)
  • 27 Mar 2000 Discontinued-unspecified phase for Crohn's disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top